Holen Sie sich die Stockscreener-App
52.47
0.10%
0.02
Handel nachbörslich:
52.47
Schlusskurs vom Vortag:
$52.45
Offen:
$51.78
24-Stunden-Volumen:
2.44M
Relative Volume:
1.17
Marktkapitalisierung:
$10.08B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
19.51
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
-4.01%
1M Leistung:
-2.93%
6M Leistung:
-12.01%
1J Leistung:
-25.28%
1-Tages-Spanne:
$51.56
$52.80
1-Wochen-Bereich:
$51.56
$55.39
52-Wochen-Spanne:
$51.56
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
52.47 | 10.07B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
BioMarin stock price target lowered to $80 at Cantor Fitzgerald By Investing.com - Investing.com UK
BioMarin stock price target lowered to $80 at Cantor Fitzgerald - Investing.com
What data driven models say about BioMarin Pharmaceutical Inc.’s futureMarket Trend Review & Accurate Trade Setup Notifications - newser.com
Price momentum metrics for BioMarin Pharmaceutical Inc. explainedJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - newser.com
BioMarin Pharmaceutical Inc. stock outlook for YEAR2025 Geopolitical Influence & Proven Capital Preservation Methods - newser.com
Can BioMarin Pharmaceutical Inc. stock hit analyst price targetsJuly 2025 EndofMonth & Low Risk Entry Point Tips - newser.com
What MACD signals say about BioMarin Pharmaceutical Inc.Market Weekly Review & Expert Curated Trade Ideas - newser.com
Can BioMarin Pharmaceutical Inc. stock reach $100 price targetMarket Movement Recap & Weekly Market Pulse Alerts - newser.com
How to manage a losing position in BioMarin Pharmaceutical Inc.Long Setup & Weekly Setup with ROI Potential - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetJuly 2025 PostEarnings & High Yield Stock Recommendations - newser.com
Understanding BioMarin Pharmaceutical Inc.’s price movementQuarterly Growth Report & Daily Oversold Stock Bounce Ideas - newser.com
Real time social sentiment graph for BioMarin Pharmaceutical Inc.2025 Fundamental Recap & AI Driven Stock Reports - newser.com
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Eyeing an 82% Potential Upside Amid Robust Growth - DirectorsTalk Interviews
Ascendis Pharma Develops Sustained-Release Therapy to Compete with BioMarin’s Voxzogo for Achondroplasia Treatment - geneonline.com
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause - BioSpace
Board of the Pension Protection Fund Invests $445,000 in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Aberdeen Group plc Has $54.04 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
BioMarin Pharmaceutical (NASDAQ:BMRN) Sets New 12-Month LowTime to Sell? - MarketBeat
Leerink Partnrs Has Negative Outlook of BMRN Q1 Earnings - MarketBeat
Callan Family Office LLC Purchases 47,264 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Biomarin Pharmaceutical stock hits 52-week low at 52.47 USD By Investing.com - Investing.com Nigeria
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know - Yahoo Finance
MarketsFinancial Advisors - FinancialContent
Biomarin Pharmaceutical stock hits 52-week low at 52.47 USD - Investing.com India
Relative strength of BioMarin Pharmaceutical Inc. in sector analysisQuarterly Investment Review & Community Trade Idea Sharing - newser.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $119.00 - MarketBeat
BioMarin Pharmaceutical's (BMRN) "Sell (D+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Duchenne Muscular Dystrophy Drugs Market Global Forecast - GlobeNewswire
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo Finance
Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts? - MSN
Biomarin Pharmaceutical expects Q3 will include acquired IPR&D charges of about $221 million - MarketScreener
BioMarin projects $221 million IPR&D charge from Inozyme acquisition - Investing.com
AAV Gene Therapy Market Size to Skyrocket at 40.1% CAGR by 2034 - GlobeNewswire Inc.
14 Biotech Stocks with High Potential - Insider Monkey
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - sharewise.com
Real time alert setup for BioMarin Pharmaceutical Inc. performanceIPO Watch & Reliable Intraday Trade Plans - newser.com
How BioMarin Pharmaceutical Inc. stock performs in stagflationM&A Rumor & Long-Term Safe Investment Ideas - newser.com
Should Positive Phase 3 PALYNZIQ Results Prompt Action From BioMarin (BMRN) Investors? - Sahm
Robeco Institutional Asset Management B.V. Increases Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc.’s (BMRN) Phenylketonuria Candidate Drug Impresses in Phase 3 Trials - MSN
Can BioMarin (BMRN) Turn PALYNZIQ Success Into a Stronger Rare Disease Growth Story? - Yahoo Finance
J. Safra Sarasin Holding AG Boosts Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Is BioMarin Pharmaceutical Inc. stock a safe buy before earningsMarket Weekly Review & Momentum Based Trading Ideas - newser.com
BioMarin Pharmaceutical (BMRN): Evaluating Valuation as PALYNZIQ Clinical Success Contrasts With 52-Week Share Price Low - Sahm
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):